Brief: Rain Therapeutics And Roche To Collaborate On Clinical Trial Of Milademetan Combination With Anti-Pd-L1 Immunotherapy For Various Solid Tumor Indications
05/01/2022 13:05
Jan 5 (Reuters) - Rain Therapeutics Inc RAIN.O :
* RAIN THERAPEUTICS AND ROCHE TO COLLABORATE ON CLINICAL
TRIAL OF
MILADEMETAN COMBINATION WITH ANTI-PD-L1 IMMUNOTHERAPY FOR
VARIOUS SOLID TUMOR INDICATIONS
* RAIN THERAPEUTICS INC - UNDER THIS AGREEMENT, RAIN IS
SPONSOR OF
ANTICIPATED CLINICAL TRIALS, AND ROCHE WILL SUPPLY ATEZOLIZUMAB
Source text for Eikon: ID:nGNX4wPHbX
Further company coverage: RAIN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rain Oncology
See all newsBrief: Rain Enhancement Technologies Holdco - May Offer Up To $25 Million In Securities From Time To Time - SEC Filing
Brief: Rain Enhancement Technologies Holdco Inc - Q1 And Q2 2025 Financial Statements Should Not Be Relied Upon Due To Accounting Error - SEC Filing
Brief: Rain Oncology Pursuant To Proposed Deal With Pathos AI
Brief: Rain Oncology To Be Acquired By Pathos AI For $1.16 In Cash Per Share Plus Contingent Value Rights
Brief: Rain Oncology Q3 Net Income USD -7.034 Million